Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Elinzanetant bulk supplier for pharma manufacturers

Elinzanetant 60 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 60 mg

Reference Brands: Lynkuet (USA/EU)

Category: Women's Health

Elinzanetant is a non‑hormonal neurokinin‑1 and neurokinin‑3 (NK1 and NK3) receptor antagonist used for the treatment of moderate to severe vasomotor symptoms (hot flashes and night sweats) associated with menopause or with hormone‑suppressive therapy in women. It works by blocking brain receptors involved in regulation of body temperature and sleep, thereby reducing the frequency and severity of hot flashes and may also help improve sleep disturbances common during menopause.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Elinzanetant — third party manufacturing & bulk supply

Elinzanetant 60 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Elinzanetant is supplied as Capsules — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Elinzanetant listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Elinzanetant →
Back to Listing

Frequently Asked Questions

Elinzanetant is used to treat moderate to severe vasomotor symptoms, such as hot flashes and night sweats, associated with menopause in adult women.

It is a synthetic neurokinin receptor antagonist that blocks neurokinin‑1 (NK1) and neurokinin‑3 (NK3) receptors in the brain, helping to regulate neuronal signalling related to thermoregulation.

The trade name is Lynkuet.

It is developed and marketed by Bayer AG.

The generic name is elinzanetant.

The brand name is Lynkuet.

It is manufactured by Bayer in their global pharmaceutical production facilities under standard drug‑manufacturing practices.

Related Products

Menotropins

Strength:
75 IU, 150 IU

Form: Injection

Reference Brands: Menopur (USA/EU), Repronex (USA/EU)

View Details
Methylergonovine Maleate

Strength:
0.2 mg, 0.2 mg/mL

Form: Tablet / Injection

Reference Brands: Methergine (USA)

View Details
Methyltestosterone

Strength:
10 mg

Form: Tablets

Reference Brands: Testred (USA/EU), Methitest (USA/EU)

View Details
Metyrapone

Strength:
250 mg

Form: Tablets

Reference Brands: Metopirone (USA/EU)

View Details
Estradiol Transdermal Patch

Strength:
0.025, 0.0375, 0.05, 0.06, 0.075, 0.1 mg/day

Form: Patch

Reference Brands: Climara®(EU & US); Vivelle-Dot®(US), Estraderm®(EU)

View Details
Clomiphene Citrate

Strength:
25 mg, 50 mg, 100 mg

Form: Tablet

Reference Brands: Clomid® (US & EU), Serophene® (US), Omifin®(EU)

View Details
Oxytocin

Strength:
5 IU/mL, 10 IU/mL

Form: Injection

Reference Brands: Pitocin®(US), Syntocinon®,Oxytip®, Oxytoc®, Gynotocin®(EU)

View Details
Levothyroxine Sodium Tablet

Strength:
25 mcg, 50 mcg, 75 mcg, 100 mcg, 125 mcg, 150 mcg, 175 mcg, 200 mcg

Form: Tablet

Reference Brands: Synthroid®, Euthyrox®, Eltroxin®(US & EU)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.